Anaphylactic reactions after COVID-19 vaccination in Germany.

Immanuel Barth, Karin Weißer, Dominique Gaston-Tischberger, Vera Mahler, Brigitte Keller-Stanislawski
{"title":"Anaphylactic reactions after COVID-19 vaccination in Germany.","authors":"Immanuel Barth,&nbsp;Karin Weißer,&nbsp;Dominique Gaston-Tischberger,&nbsp;Vera Mahler,&nbsp;Brigitte Keller-Stanislawski","doi":"10.5414/ALX02374E","DOIUrl":null,"url":null,"abstract":"<p><p>. For the COVID-19 vaccines used in Germany, severe allergic (anaphylactic) reactions after vaccination have been reported in very rare cases. While Comirnaty and Spikevax are mRNA vaccines, Vaxzevria and Jcovden comprise vector vaccines, and Nuvaxovid a recombinant spike protein vaccine. The reporting rate of anaphylaxis after mRNA vaccination was higher in females receiving their first vaccination dose, with 0.97 and 1.12 reports per 100,000 vaccinations for Comirnaty and Spikevax, respectively, compared with vaccinated males and subsequent vaccinations. The Paul-Ehrlich-Institut (PEI) investigated 106 responses of 321 cases of confirmed anaphylactic reactions concerning subsequent allergy testing and revaccination with a COVID-19 vaccine. The collected data indicate that only a small proportion of cases (22%) were IgE-mediated reactions. A large proportion (73%) of patients could be revaccinated under precautionary measures without recurrence of anaphylaxis. The pathomechanism of the majority of anaphylactic reactions remains unclear and should be investigated in further studies.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"7 ","pages":"90-100"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088875/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologie Select","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5414/ALX02374E","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

. For the COVID-19 vaccines used in Germany, severe allergic (anaphylactic) reactions after vaccination have been reported in very rare cases. While Comirnaty and Spikevax are mRNA vaccines, Vaxzevria and Jcovden comprise vector vaccines, and Nuvaxovid a recombinant spike protein vaccine. The reporting rate of anaphylaxis after mRNA vaccination was higher in females receiving their first vaccination dose, with 0.97 and 1.12 reports per 100,000 vaccinations for Comirnaty and Spikevax, respectively, compared with vaccinated males and subsequent vaccinations. The Paul-Ehrlich-Institut (PEI) investigated 106 responses of 321 cases of confirmed anaphylactic reactions concerning subsequent allergy testing and revaccination with a COVID-19 vaccine. The collected data indicate that only a small proportion of cases (22%) were IgE-mediated reactions. A large proportion (73%) of patients could be revaccinated under precautionary measures without recurrence of anaphylaxis. The pathomechanism of the majority of anaphylactic reactions remains unclear and should be investigated in further studies.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
德国COVID-19疫苗接种后的过敏反应。
。对于在德国使用的COVID-19疫苗,在极少数病例中报告了接种后的严重过敏(过敏)反应。Comirnaty和Spikevax是mRNA疫苗,Vaxzevria和Jcovden是载体疫苗,Nuvaxovid是重组刺突蛋白疫苗。在首次接种mRNA疫苗的女性中,报告的过敏反应率较高,Comirnaty和Spikevax疫苗每10万次接种中分别有0.97和1.12例报告,与接种疫苗的男性和随后接种的男性相比。保罗-埃利希研究所(PEI)调查了321例确诊过敏反应的106例反应,涉及随后的过敏试验和重新接种COVID-19疫苗。收集的数据表明,只有一小部分病例(22%)是ige介导的反应。很大比例(73%)的患者可以在预防措施下重新接种疫苗,而不会出现过敏反应复发。大多数过敏反应的发病机制尚不清楚,有待进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Vegan diets from an allergy point of view - Position paper of the DGAKI working group on food allergy. Clinical endpoints in allergen immunotherapy: State of the art 2022. Allergic asthma: An indication for allergen immunotherapy. Allergen challenge tests in allergen immunotherapy: State of the art. Real-life evidence in allergen immunotherapy: Moving forward with mHealth apps.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1